Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M
Marie Curie Research Wing, Mount Vernon Hospital, Northwood, Middlesex, UK.
Radiother Oncol. 1997 Aug;44(2):123-36. doi: 10.1016/s0167-8140(97)00094-7.
Continuous, hyperfractionated, accelerated radiotherapy (CHART) has shown promise of improved tumour control and reduced late morbidity in pilot studies and has now been tested in a multicentre randomised controlled clinical trial.
Patients with squamous cell cancer in the main sites within the head and neck region with the general exception of early T1 N0 tumours were entered into the study by 11 centres. There was a 3:2 randomisation to either CHART, where a dose of 54 Gy was given in 36 fractions over 12 days, or to conventional therapy where 66 Gy was given in 33 fractions over 6.5 weeks. A total of 918 patients were included over a 5 year period from March 1990.
ACUTE MORBIDITY: Acute radiation mucositis was more severe with CHART, occurred earlier but settled sooner and was in nearly all cases healed by 8 weeks in both arms. Skin reactions were less severe and settled more quickly in the CHART treated patients. TUMOUR CONTROL AND SURVIVAL: Life table analyses of loco-regional control, primary tumour control, nodal control, disease-free interval, freedom from metastasis and survival showed no evidence of differences between the two arms. In exploratory subgroup analyses there was evidence of a greater response to CHART in younger patients (P = 0.041) and poorly differentiated tumours appeared to fare better with conventional radiotherapy (P = 0.030). In the larynx there was evidence of a trend towards increasing benefit with more advanced T stage (P = 0.002). LATE TREATMENT RELATED MORBIDITY: Osteoradionecrosis occurred in 0.4% of patients after CHART and 1.4% of patients after conventional radiotherapy. The incidence of chondritis or cartilage necrosis was similar in both arms. Life table analysis showed evidence of reduced severity in a number of late morbidities in favour of CHART. These were most striking for skin telangiectasia, superficial and deep ulceration of the mucosa and laryngeal oedema.
Similar local turnout control was achieved by CHART as compared with conventional radiotherapy despite the reduction in total dose from 66 to 54 Gy supporting the importance of repopulation as a cause of radiation failure. The effects seen in advanced laryngeal cancer and those related to histological differentiation need further study. Reduced late morbidity is a factor which together with patient preference should be considered in the decision as to the programme of radiotherapy to employ in the curative treatment of head and neck cancer.
在前期研究中,连续超分割加速放疗(CHART)已显示出改善肿瘤控制及降低晚期发病率的前景,目前已在一项多中心随机对照临床试验中进行了验证。
11个中心将头颈部主要部位的鳞状细胞癌患者纳入研究,但早期T1 N0肿瘤患者一般除外。按3:2随机分为CHART组(在12天内分36次给予54 Gy剂量)或传统治疗组(在6.5周内分33次给予66 Gy剂量)。从1990年3月起的5年期间,共纳入918例患者。
急性毒性反应:CHART组急性放射性粘膜炎更严重,出现更早但消退更快,几乎所有病例在8周时双臂均愈合。CHART治疗的患者皮肤反应较轻且消退更快。肿瘤控制与生存:局部区域控制、原发肿瘤控制、淋巴结控制、无病间期、无转移生存期和总生存期的生命表分析显示,两组之间无差异。在探索性亚组分析中,有证据表明年轻患者对CHART反应更大(P = 0.041),低分化肿瘤似乎采用传统放疗效果更好(P = 0.030)。在喉癌中,有证据表明随着T分期增加,CHART的获益呈增加趋势(P = 0.002)。晚期治疗相关毒性反应:CHART组0.4%的患者发生骨放射性坏死,传统放疗组为1.4%。两组软骨炎或软骨坏死的发生率相似。生命表分析显示,多项晚期毒性反应的严重程度降低,支持CHART。皮肤毛细血管扩张、粘膜浅表和深部溃疡以及喉水肿最为明显。
与传统放疗相比,CHART实现了相似的局部肿瘤控制,尽管总剂量从66 Gy降至54 Gy,这支持了再增殖作为放疗失败原因的重要性。在晚期喉癌中观察到的效应以及与组织学分化相关的效应需要进一步研究。降低晚期发病率是一个因素,在决定采用何种放疗方案来根治头颈部癌时,应与患者偏好一并考虑。